1. Scrip
  2. >>Therapy Areas

Clinical Data And Cash: Inflammation Focused InflaRx Hots Up

 
• By Sukaina Virji

Positive Phase II data in sepsis and a €31m private financing round: 2016 has been a busy year for inflammation focused German biotech InflaRx.

InflaRx GMBH, based in Jena, Germany, raised €31m in July this year to advance Phase II development of its lead drug candidate IFX-1, a first-in-class monoclonal anti-complement C5a antibody.

The plan is to use the funds to pursue IFX-1 in various acute and chronic inflammatory indications. In January, InflaRx...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.